Key Points
- Insider sale: On March 4, director William Guyer sold 8,233 shares at an average price of $35.99 for a total of $296,305.67, reducing his ownership by 78.68% to 2,231 shares (disclosed in an SEC filing).
- Earnings miss: Corcept reported Q results on Feb. 24 with EPS of $0.20 versus a $0.33 consensus and revenue of $202.13M versus $254.94M, missing estimates despite 11.1% YoY revenue growth; the stock has a market cap of about $3.6B and a PE near 41.
- Legal risk: Multiple plaintiff firms have issued securities class action notices over alleged investor misstatements related to FDA warnings and the Relacorilant NDA, with an April 21, 2026 lead‑plaintiff deadline that could increase litigation costs and pressure the stock.
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider William Guyer sold 8,233 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $35.99, for a total value of $296,305.67. Following the transaction, the insider owned 2,231 shares of the company's stock, valued at $80,293.69. This represents a 78.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
William Guyer also recently made the following trade(s):
- On Tuesday, February 3rd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $40.87, for a total transaction of $817,400.00.
- On Tuesday, January 6th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $35.18, for a total value of $703,600.00.
Corcept Therapeutics Price Performance
CORT opened at $33.87 on Friday. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $117.33. The company's 50 day simple moving average is $39.59 and its 200 day simple moving average is $64.47. The stock has a market capitalization of $3.60 billion, a PE ratio of 41.31 and a beta of 0.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The business had revenue of $202.13 million during the quarter, compared to analyst estimates of $254.94 million. During the same period in the previous year, the company earned $0.26 EPS. Corcept Therapeutics's revenue was up 11.1% on a year-over-year basis. As a group, sell-side analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.
Institutional Investors Weigh In On Corcept Therapeutics
A number of hedge funds have recently bought and sold shares of CORT. Royal Bank of Canada grew its position in Corcept Therapeutics by 18.9% in the 1st quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company's stock worth $1,757,000 after purchasing an additional 2,444 shares during the last quarter. Amundi acquired a new stake in shares of Corcept Therapeutics in the 1st quarter valued at $450,000. NewEdge Advisors LLC bought a new stake in Corcept Therapeutics during the first quarter worth about $518,000. Envestnet Asset Management Inc. grew its position in Corcept Therapeutics by 22.3% during the 2nd quarter. Envestnet Asset Management Inc. now owns 38,847 shares of the biotechnology company's stock worth $2,851,000 after acquiring an additional 7,077 shares during the last quarter. Finally, Bank of Montreal Can increased its stake in shares of Corcept Therapeutics by 2.1% in the second quarter. Bank of Montreal Can now owns 17,351 shares of the biotechnology company's stock valued at $1,274,000 after buying an additional 353 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors.
More Corcept Therapeutics News
Here are the key news stories impacting Corcept Therapeutics this week:
- Positive Sentiment: COR T’s Korlym revenue momentum: Zacks highlights a 13% Y/Y sales rise for Korlym in 2025 and projects 2026 revenue of $900M–$1B, suggesting solid underlying product sales even as competitive and legal risks persist. Korlym revenue article
- Neutral Sentiment: Short‑interest data published for early March appears inconsistent/zero (likely a data/reporting glitch) and does not provide clear evidence of increased shorting pressure at this time — investors should treat those figures cautiously. (Multiple short‑interest entries in news feed showed 0 shares / NaN changes.)
- Negative Sentiment: Hagens Berman and other firms: A securities class action (Allegheny County Employees' Retirement System v. Corcept et al.) was flagged this week alleging the company and executives misled investors, citing FDA warnings and "evidence gaps" around the Relacorilant NDA that previously triggered a ~50% stock drop. Lead‑plaintiff deadline is April 21, 2026. Hagens Berman notice
- Negative Sentiment: Multiple plaintiff firms (Bronstein, Rosen, Pomerantz, Schall, Glancy, DJS, ClaimsFiler, etc.) have issued alerts encouraging investors to join/lead the class action based on purchases between Oct 31, 2024 and Dec 30, 2025 — this amplifies media attention and could increase settlement/defense costs and management distraction. Example: Bronstein notice. Bronstein notice
- Negative Sentiment: Schall/Rosen/Pomerantz & others reiterate class‑period and April 21 deadline; aggregated press releases increase likelihood of large plaintiff turnout and publicity — a material near‑term catalyst pressuring the stock. Example: Schall Law Firm reminder. Schall Law Firm notice
Wall Street Analysts Forecast Growth
CORT has been the topic of several analyst reports. Weiss Ratings restated a "hold (c)" rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Wolfe Research lowered Corcept Therapeutics from a "peer perform" rating to an "underperform" rating and set a $30.00 price target for the company. in a research note on Wednesday, December 31st. Truist Financial set a $50.00 price objective on shares of Corcept Therapeutics in a research note on Wednesday, December 31st. HC Wainwright cut their target price on Corcept Therapeutics from $105.00 to $67.00 and set a "buy" rating on the stock in a research report on Friday, February 20th. Finally, Canaccord Genuity Group raised their price objective on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, January 23rd. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $77.17.
Read Our Latest Report on CORT
About Corcept Therapeutics
(
Get Free Report)
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
